Last update 08 May 2025

Cipla BioTec Ltd.

Holding Company|2008|India

Overview

Tags

Nervous System Diseases
Endocrinology and Metabolic Disease
Urogenital Diseases
Hormone

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
no Data
No Data
Disease DomainCount
Endocrinology and Metabolic Disease1
Nervous System Diseases1
Top 5 Drug TypeCount
Hormone1

Related

2
Drugs associated with Cipla BioTec Ltd.
CBT-125
Target-
Mechanism-
Active Org.
Cipla BioTec Ltd.
Originator Org.
Cipla BioTec Ltd.
Active Indication
Diabetes Insipidus [+1]
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
India
First Approval Date30 Apr 2016
Bevacizumab biosimilar(Cipla Ltd.)
Target
VEGF-A
Mechanism
VEGF-A inhibitors [+1]
Active Org.
Cipla Australia Pty Ltd.
Originator Org.
Cipla Ltd.Cipla Ltd.
Active Indication
Advanced Renal Cell Carcinoma [+11]
Inactive Indication
metastatic non-small cell lung cancer
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
Australia
First Approval Date02 Nov 2021
1
Clinical Trials associated with Cipla BioTec Ltd.
NCT02879097
/ Unknown statusPhase 3
Efficacy, Safety & Immunogenicity Study of CBT124 & EU-sourced Avastin® in Combination With Carboplatin and Paclitaxel in First-line Treatment in (NSCLC)
100 Clinical Results associated with Cipla BioTec Ltd.
Login to view more data
0 Patents (Medical) associated with Cipla BioTec Ltd.
Login to view more data
100 Deals associated with Cipla BioTec Ltd.
Login to view more data
100 Translational Medicine associated with Cipla BioTec Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 12 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Approved
1
1
Other
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
CBT-125
Diabetes Insipidus
More
Approved
Bevacizumab biosimilar(Cipla Ltd.)
 ( VEGF-A )		metastatic non-small cell lung cancer
More
Pending
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free